C4 Therapeutics. has been granted a patent for compounds that degrade the BRD9 protein, aimed at treating disorders associated with BRD9, such as abnormal cellular proliferation. The patent includes a method for administering these compounds effectively. GlobalData’s report on C4 Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on C4 Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. C4 Therapeutics's grant share as of July 2024 was 12%. Grant share is based on the ratio of number of grants to total number of patents.
Brd9 protein degradation compounds for treating related disorders
The granted patent US12049464B2 outlines a method for treating disorders mediated by the BRD9 protein. The primary focus of the claims is the administration of specific compounds, defined by various chemical formulas, in effective amounts to address these disorders. The claims detail a series of structural modifications to the compounds, including specific substitutions and configurations, such as the presence of NH groups, CH2 linkages, and methyl groups. Notably, the patent identifies synovial sarcoma and SMARCB1-perturbed cancers as specific disorders that can be targeted using the described compounds.
The claims further elaborate on the structural characteristics of the compounds, emphasizing their potential therapeutic applications in treating BRD9-mediated conditions. The specificity of the compounds and their structural variations suggest a tailored approach to targeting the BRD9 protein, which is implicated in certain cancer types. By delineating the chemical structures and their corresponding applications, the patent provides a framework for developing targeted therapies aimed at improving treatment outcomes for patients with these specific cancers.
To know more about GlobalData’s detailed insights on C4 Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
